ocrelizumab

Known as: rhuMAb 2H7 
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2017
Highly Cited
2017
BACKGROUND B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
OBJECTIVE The objective was to determine the safety of ocrelizumab (OCR) in patients with rheumatoid arthritis (RA). METHODS… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). METHODS… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
OBJECTIVE To evaluate the safety and efficacy of ocrelizumab plus methotrexate (MTX) or leflunomide (LEF) in patients with active… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
BACKGROUND Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was studied in a first-in-human trial in rheumatoid arthritis… (More)
Is this relevant?
Review
2008
Review
2008
Biogen Idec Inc, Genentech Inc, Roche Holding AG and Chugai Pharmaceutical Co Ltd are developing ocrelizumab, a humanized mAb… (More)
Is this relevant?